 -- Pivotal Phase 3 EMANATE trial planned in patients with heterozygous POMC, PCSK1 or LEPR, and SRC1 or SH2B1 deficiency obesities -- -- EMANATE, as well as Phase 2 DAYBREAK trial evaluating setmelanotide in 31 new genes, Phase 3 pediatrics trial and Phase 3 trials of weekly setmelanotide formulation all expected to initiate in 2H 2021 -- -- Updated Uncovering Rare Obesity genetic test with expanded gene panel launched in July -- -- Company to host conference call at 8 a.m. ET today -- CAMBRIDGE, Mass., Aug. 03, 2021 GLOBE NEWSWIRE -- Rhythm Pharmaceuticals, Inc. Nasdaq: RYTM, a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced a significant expansion of its clinical development program for setmelanotide with five new planned Phase 2 and 3 clinical trials. Rhythm will review these updates on its second quarter 2021 financial results and business update conference call today at 8 a.m. ET. 